Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON: Iberdomide, Cyclophosphamide, and Dexamethasone in RRMM
NCT04392037Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iberdomide in multiple myeloma (MM), sponsored by Amsterdam University Medical Center. Primary endpoint: Progression-Free Survival up to 5 years. Started Feb 2021; status: active, not recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04392037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392037.